Search Within

Mark Weiss

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Meeting Abstract (22)
  2. Journal Article (8)
  3. Book Section (4)
Groups
  1. Adult Leukemia (34)
  2. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (34)
  3. Center for Hematologic Malignancies (34)
  4. Center for Molecular Imaging and Biotechnology (34)
  5. Department of Medicine (34)
  6. GSK Faculty (34)

More Groups

People
  1. David Scheinberg (34)
  2. Peter Maslak (30)
  3. Joseph Jurcic (15)
  4. Ellin Berman (10)
  5. Nicole Lamanna (9)
  6. Alison Gencarelli (8)

More People

Years
  1. 2010 (1)
  2. 2009 (1)
  3. 2008 (1)
  4. 2006 (1)
  5. 2005 (4)
  6. 2004 (3)

More Years

Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (5)
  3. Leukemia (4)
  4. Cancer: Principles and Practice of Oncology. 5th ed (2)
  5. Cancer: Principles and Practice of Oncology. 6th ed (1)
  6. Cancer: Principles and Practice of Oncology. 7th ed (1)
Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (5)
  3. Nature Publishing Group (4)
  4. Lippincott Williams & Wilkins (2)
  5. Lippincott-Raven (2)

Results (34)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    Journal Article

    Maslak, P. G.; Dao, T.; Krug, L. M.; Chanel, S.; Korontsvit, T.; Zakhaleva, V.; Zhang, R.; Wolchok, J. D.; Yuan, J.; Pinilla-Ibarz, J.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: Molecular remissions predict for durable complete responses
    Journal Article

    Lamanna, N.; Jurcic, J. G.; Noy, A.; Maslak, P.; Gencarelli, A. N.; Panageas, K. S.; Heaney, M. L.; Brentjens, R. J.; Golde, D. W.; Scheinberg, D. A.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Sequential cytarabine and alpha-particle immunotherapy with bismuth-213 ((213)Bi)-labeled-HuM195 (lintuzumab) for acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T.; McDevitt, M. R.; Mulford, D. A.; Pandit-Taskar, N.; Weiss, M. A.; Heaney, M. L.; Chanel, S.; Morgenstern, A.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Management of acute leukemias
    Book Section

    Scheinberg, D. A.; Maslak, P. G.; Weiss, M. A.
    In DeVita, V. T.; Hellman, S.; Rosenberg, S. A. (Eds.) Cancer: Principles and Practice of Oncology. 7th ed (2005)

    Fulltext@MSK | Save
  • A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL
    Meeting Abstract

    Weiss, M. A.; Heffner, L.; Lamanna, N.; Kalaycio, M.; Schiller, G.; Coutre, S.; Maslak, P.; Jurcic, J.; Panageas, K.; Scheinberg, D. A.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Induction with combined modality therapy followed by immunomodulated post remission therapy for newly diagnosed acute myeloid leukemia (AML)
    Meeting Abstract

    Gupta, S.; Weiss, M. A.; Jurcic, J. G.; Chanel, S.; Wilson, B. A.; Biederman, E.; Berman, E.; Scheinberg, D. A.; Maslak, P. G.
    Blood (2005)

    Fulltext@MSK | Save
  • Pentostatin and cyclophosphamide compared to pentostatin, cyclophosphamide, and rituximab as salvage therapy for patients with chronic lymphocytic leukemia
    Meeting Abstract

    Weiss, M. A.; Lamanna, N.; Kalaycio, M.; Jurcic, J.; Maslak, P.; Gencarelli, A.; Scheinberg, D.; Horgan, D.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Meeting Abstract

    Mulford, D. A.; Pandit-Taskar, N.; McDevitt, M. R.; Finn, R. D.; Weiss, M. A.; Apostolidis, C.; Morgenstern, A.; Divgi, C. R.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2004)

    Fulltext@MSK | Save